Nick B. Tressler

CIK: 0001794362

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VTGN

Vistagen Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

VTGN
Vistagen Therapeutics, Inc.
Jun 30, 2026
Award(A)
Direct
11.7K shares at avg. $0.19$2K
VTGN
Vistagen Therapeutics, Inc.
Apr 7, 2026
Award(A)
Incentive Stock Option (right to buy)
Direct
75K shares-
VTGN
Vistagen Therapeutics, Inc.
Dec 1, 2025
Award(A)
Common Stock (Right to Buy)
Direct
150K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A)	11,712	$0.19	$2,250	Direct
Apr 7, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	75,000	-	-	Direct
Dec 1, 2025	VTGN Vistagen Therapeutics, Inc.	Award(A) Common Stock (Right to Buy)	150,000	-	-	Direct

1-3 of 3 transactions

About Tressler Nick B.

Tressler Nick B. (SEC CIK 0001794362) files insider reports with the SEC as Chief Financial Officer of Vistagen Therapeutics, Inc. (VTGN).

Signal8 holds 4 ownership filings by Tressler Nick B. (1 Form 3, 3 Form 4), filed between Dec 4, 2025 and Jul 2, 2026. Those filings report 3 transactions, from Dec 1, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tressler Nick B.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Tressler Nick B.

Jun 30, 2026: Grant or award of VTGN shares (Form 4, code A).
Apr 7, 2026: Grant or award of VTGN derivative securities (Form 4, code A).
Dec 1, 2025: Grant or award of VTGN derivative securities (Form 4, code A).

Other insiders filing for Vistagen Therapeutics, Inc. (VTGN)

Williamson Douglas J, Officer
Adler Reid G., Chief Legal Officer
Singh Shawn, President and CEO
Angelov Angel S, Chief Medical Officer
Prince Joshua S., Chief Operating Officer
Cote Elissa S., Chief Corp Development Officer

How to read Form 4 transaction codes